Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Malar J ; 16(1): 188, 2017 05 04.
Article in English | MEDLINE | ID: mdl-28472957

ABSTRACT

BACKGROUND: Malaria remains one of the most important infectious diseases. Treatment options for severe malaria are limited and the choline analogue SAR97276A is a novel chemical entity that was developed primarily as treatment for severe malaria. Before starting clinical investigations in severely ill malaria patients, safety and efficacy of SAR97276A was studied in patients with uncomplicated malaria. Here, we summarize two open-label, multi-center phase 2 trials assessing safety and efficacy of parenterally administered SAR97276A in African adults and children with falciparum malaria. RESULTS: Study 1 was conducted in Burkina Faso, Gabon, Benin and Tanzania between August 2008 and July 2009 in malaria patients in an age de-escalating design (adults, children). A total of 113 malaria patients received SAR97276A. Adults were randomized to receive a single dose SAR97296A given either intramuscularly (IM) (0.18 mg/kg) or intravenously (IV) (0.14 mg/kg). If a single dose was not efficacious a second adult group was planned to test a three dose regimen administered IM once daily for 3 days. Single dose SAR97276A showed insufficient efficacy in adults (IM: 20 of 34 cured, 59%; and IV: 23/30 cured, 77%). The 3-day IM regimen showed acceptable efficacy in adults (27/30, 90%) but not in children (13/19, 68%). SAR97276A was well tolerated but no further groups were recruited due lack of efficacy. Study 2 was conducted between October 2011 and January 2012 in Burkina Faso, Gabon and Kenya. SAR97276A administered at a higher dose given IM was compared to artemether-lumefantrine. The study population was restricted to underage malaria patients to be subsequently enrolled in two age cohorts (teenagers, children). Rescue therapy was required in all teenaged malaria patients (8/8) receiving SAR97276A once daily (0.5 mg/kg) for 3 days and in 5 out of 8 teenaged patients treated twice daily (0.25 mg/kg) for 3 days. All patients (4/4) in the control group were cured. The study was stopped, before enrollment of children, due to lack of efficacy but the overall safety profile was good. CONCLUSIONS: Monotherapy with SAR97276A up to twice daily for 3 days is not an efficacious treatment for falciparum malaria. SAR97276A will not be further developed for the treatment of malaria. Trial registration at clinicaltrials.gov: NCT00739206, retrospectively registered August 20, 2008 for Study 1 and NCT01445938 registered September 26, 2011 for Study 2.


Subject(s)
Malaria, Falciparum/drug therapy , Thiazoles/therapeutic use , Adolescent , Adult , Africa South of the Sahara/epidemiology , Antimalarials/adverse effects , Antimalarials/pharmacology , Antimalarials/therapeutic use , Child , Child, Preschool , Cohort Studies , Female , Humans , Incidence , Infant , Malaria, Falciparum/epidemiology , Male , Middle Aged , Plasmodium falciparum/drug effects , Plasmodium falciparum/physiology , Thiazoles/adverse effects , Thiazoles/pharmacology , Treatment Outcome , Young Adult
2.
J Infect Dis ; 196(11): 1595-602, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-18008242

ABSTRACT

BACKGROUND: Intermittent preventive treatment aims to maximize the protective effects of malaria chemoprophylaxis while minimizing the deleterious effects. METHODS: In Gabon, 1189 infants received either sulfadoxine-pyrimethamine (SP; 250 and 12.5 mg, respectively) or placebo at 3, 9, and 15 months of age. Children were actively followed-up until 18 months of age. RESULTS: In the intention-to-treat population at 18 months of follow-up, 84 children (17%) in the SP group had > or =1 episode of anemia, versus 108 (21%) in the placebo group (protective efficacy, 22% [95% confidence interval {CI}, -1% to 40%]; P=.06). In the intervention group, there were 66 episodes during 485 person-years at risk, compared with 79 episodes during 497 years in the placebo group (protective efficacy, 17% [95% CI, -24% to 45%; P=.36). The effects were similar at 12 months of follow-up. The study drug was safe and well tolerated. CONCLUSIONS: The intervention was efficacious, producing a reduction in risk for anemia but a smaller effect against malaria. It is a valuable additional tool to control malaria in a highly vulnerable age group. Remaining important questions are currently being addressed in further studies. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00167843.


Subject(s)
Antimalarials/administration & dosage , Malaria, Falciparum/prevention & control , Parasitemia/prevention & control , Pyrimethamine/administration & dosage , Sulfadoxine/administration & dosage , Anemia/chemically induced , Anemia/epidemiology , Antimalarials/adverse effects , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Female , Gabon/epidemiology , Hematocrit , Hemoglobins/metabolism , Humans , Incidence , Infant , Kaplan-Meier Estimate , Malaria, Falciparum/blood , Malaria, Falciparum/epidemiology , Male , Parasitemia/blood , Parasitemia/epidemiology , Parasitemia/parasitology , Patient Selection , Pyrimethamine/adverse effects , Research Design , Sulfadoxine/adverse effects , Treatment Outcome
3.
Am J Trop Med Hyg ; 77(5): 939-42, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17984357

ABSTRACT

Plasmodium falciparum, the most common malarial parasite in sub-Saharan Africa, accounts for a high number of deaths in children less than five years of age. In malaria-endemic countries with stable transmission, semi-immunity is usually acquired after childhood. For adults, severe malaria is rare. Infected adults have either uncomplicated malaria or asymptomatic parasitemia. During a period of one year, we screened 497 afebrile males to investigate the prevalence of asymptomatic P. falciparum parasitemia in villages near Lambaréné, Gabon by use of three different methods. A total of 52% of the individuals had parasites detected by a subtelomeric variable open reading frame polymerase chain reaction (stevor-PCR), 27% of the rapid diagnostic test results were positive, and 12% of the thick blood smears with low parasitemias had P. falciparum. Most positive cases were only detected by the stevor-PCR. Asymptomatic P. falciparum parasitemia in adults living in a malaria-endemic country is frequent.


Subject(s)
Malaria, Falciparum/epidemiology , Plasmodium falciparum , Adolescent , Adult , Animals , Carrier State/epidemiology , Gabon/epidemiology , Humans , Malaria, Falciparum/blood , Malaria, Falciparum/diagnosis , Male , Middle Aged , Parasitemia/epidemiology , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...